ResApp deal dips on test results

Posted on


Pfizer takeover goal ResApp has had its valuation minimize after its COVID-19 detecting cough software failed to fulfill efficiency necessities wanted to lock in an improved all-cash provide for the business.

Source Article

Leave a Reply

Your email address will not be published.